Advertisement
Orion Nutraceuticals Inc.

Orion Nutraceuticals Inc. Fundamental Analysis

ORI.CNCNQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.40
$0.00(0.00%)
Canadian Market is Open · 10:54
Advertisement

Orion Nutraceuticals Inc. Fundamental Analysis

Orion Nutraceuticals Inc. (ORI.CN) shows weak financial fundamentals with a PE ratio of -189.63, profit margin of 0.00%, and ROE of 6.54%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.00

Areas of Concern

ROE6.54%
Operating Margin0.00%
Cash Position1.65%
Current Ratio0.17
We analyze ORI.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 35.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
35.3/100

We analyze ORI.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

ORI.CN struggles to generate sufficient returns from assets.

ROA > 10%
-31.96%

Valuation Score

Excellent

ORI.CN trades at attractive valuation levels.

PE < 25
-189.63
PEG Ratio < 2
-0.00

Growth Score

Weak

ORI.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ORI.CN shows balanced financial health with some risks.

Debt/Equity < 1
-0.08
Current Ratio > 1
0.17

Profitability Score

Weak

ORI.CN struggles to sustain strong margins.

ROE > 15%
6.54%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ORI.CN Expensive or Cheap?

P/E Ratio

ORI.CN trades at -189.63 times earnings. This suggests potential undervaluation.

-189.63

PEG Ratio

When adjusting for growth, ORI.CN's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Orion Nutraceuticals Inc. at -12.01 times its book value. This may indicate undervaluation.

-12.01

EV/EBITDA

Enterprise value stands at -191.43 times EBITDA. This is generally considered low.

-191.43

How Well Does ORI.CN Make Money?

Net Profit Margin

For every $100 in sales, Orion Nutraceuticals Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $6.54 in profit for every $100 of shareholder equity.

6.54%

ROA

Orion Nutraceuticals Inc. generates $-31.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

-31.96%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

ORI.CN converts -0.49% of its market value into free cash.

-0.49%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-189.63

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-12.01

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.17

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.07

vs 25 benchmark

ROA

Return on assets percentage

-0.32

vs 25 benchmark

ROCE

Return on capital employed

0.32

vs 25 benchmark

How ORI.CN Stacks Against Its Sector Peers

MetricORI.CN ValueSector AveragePerformance
P/E Ratio-189.6333.74 Better (Cheaper)
ROE6.54%404.00% Weak
Net Margin0.00%-40219.00% (disorted) Weak
Debt/Equity-0.080.81 Strong (Low Leverage)
Current Ratio0.175.53 Weak Liquidity
ROA-31.96%-281.00% (disorted) Weak

ORI.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Orion Nutraceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ